Hepatocellular Carcinoma (HCC) Clinical Trial
Official title:
The Potential Role of Ga-68-PSMA in Staging, Restaging and Monitoring Response in Primary Liver Cancer: Comparison With F-18-FDG
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause
of cancer-related deaths in the world. Hepatitis C virus (HCV) is the most common underlying
cause of cirrhosis and HCC in the western world.
The staging of the disease is done by combining blood tests and imaging tests. Ultrasound
scanning, computed tomograph (CT) and magnetic resonance imaging (MRI) scans are methods
based on identifying or significant change in the liver.
Those changes are sometimes difficult to identify, especially when there are changes in
liver structure resulting from disease, such as cirrhosis of the liver.
In many cases it is also difficult to detect secondary scattering in anatomical tests, such
as identifying a disease in normal size lymph nodes or early skeletal dissociation.
Functional imaging is not based on structural changes, but on the ability to detect changes
in the function and properties of the tissue, such as a change in the cell's metabolic
consumption or the presence of proteins that characterize the tumor tissue.PET scans can
show tumor cell activity (the cancer cells are more aggressive, get more sugar and therefore
see more absorption in PET), detect small tumors and metastases outside the liver (because
they do a whole body test). To complete this test, a CT scan is also performed on the same
device (PET-CT scanner).
There is a new material called prostate-specific mRNA that is marked with gallium isotope
(Ga-68-PSMA). It is the substance that is absorbed into the cells of the blood vessels of
the tumor. The Ga-68-PSMA is now widely used in the diagnosis of prostate cancer. The new
researches also found the possibility of using Ga-68-PSMA in primary liver cancer in
patients because of the over-expression of the antigen in the blood vessels.
Therefore, the tests with Ga-68-PSMA and F-18-FDG will complement each other and will give a
complete picture of the extent of the disease.
Each patient has individual characteristics of the tumor, and according to the results it
will be possible to adapt the test to the patient with the appropriate material for the
disease and this will be effective for the decision to treat and follow up.
At the end of the study it will be possible to offer the study participant the appropriate
functional imaging test.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03007212 -
Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis
|
Phase 4 | |
| Terminated |
NCT03236649 -
The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
|
Phase 3 | |
| Withdrawn |
NCT04044326 -
The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant Liver Tumors
|
N/A | |
| Recruiting |
NCT04687969 -
Multimodal Machine Learning Characterization of Solid Tumors
|
||
| Completed |
NCT02562755 -
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
|
Phase 3 | |
| Withdrawn |
NCT02406508 -
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
|
Phase 2 | |
| Completed |
NCT01972672 -
The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT01247298 -
A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma
|
Phase 0 | |
| Completed |
NCT03735628 -
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02188901 -
Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study
|
N/A | |
| Active, not recruiting |
NCT04522908 -
Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function
|
Phase 2 | |
| Terminated |
NCT01433016 -
Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI
|
Phase 2 | |
| Withdrawn |
NCT04465734 -
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
|
Phase 3 | |
| Recruiting |
NCT05057013 -
HMBD-001 in Advanced HER3 Positive Solid Tumours
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03753659 -
IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
|
Phase 2 | |
| Terminated |
NCT03144661 -
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT01821482 -
A Study of DC-CIK to Treat Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT03516071 -
A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
|
Phase 2 | |
| Completed |
NCT01761266 -
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
|
Phase 3 | |
| Not yet recruiting |
NCT06345001 -
A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer
|
Phase 1 |